FDA Seeks to Strip Suicide Warning From GLP‑1 Weight‑Loss Drugs as Labels Expand
Updated (4 articles)
FDA Requests Removal of Suicide Warning After Comprehensive Review The Food and Drug Administration formally asked manufacturers of Wegovy, Saxenda and Zepbound/Zepzola to delete the suicidal‑behavior warning from their labels. A meta‑analysis covering 91 trials and 107,910 participants found no statistically significant increase in suicidal ideation, behavior, anxiety or depression compared with placebo [2][3][4]. An additional claims‑based observational study reached the same conclusion, showing no elevated risk among new GLP‑1 users [2][3]. The agency frames the move as correcting an overcautious warning that has persisted since the drugs’ 2005 approval [2][3][4].
GLP‑1 Agonists Widely Used for Diabetes and Obesity About 12 % of U.S. adults were taking a GLP‑1 medication as of November, primarily for weight loss or type 2 diabetes management [1]. Wegovy and Zepbound are marketed for obesity, while Saxenda and the older formulations were first approved to improve blood‑sugar control and reduce cardiovascular risk [2][3][4]. The suicide‑risk warning has been on the label since the 2005 FDA approval of the drug class [2][3][4]. Regulators cite the large user base as a reason to ensure labeling accurately reflects current safety data [2][3][4].
Unregulated ‘GLP‑1 Friendly’ Labels Appear on Packaged Foods Supermarkets now carry meals and snacks bearing “GLP‑1 Friendly” stickers that highlight protein and fiber content, but the FDA does not regulate these claims [1]. The USDA has approved the label for some products while noting there is no official standard for the term and that it must not be misleading [1]. Brands such as Nestlé’s Vital Pursuit line and Conagra’s Healthy Choice meals have adopted the label following consumer feedback [1]. Nutritionists caution shoppers to still check for hidden sugar or sodium, as the label alone does not guarantee overall nutrient density [1].
Nutrition Experts Advise Protein‑Rich, Fiber‑Dense Meals for Users Because GLP‑1 drugs suppress appetite, dietitians recommend 20‑30 g of protein per meal and roughly 1.2 g of protein per kilogram of body weight each day [1]. Fiber targets of about 14 g per 1,000 kcal are also advised to support satiety and gut health [1]. Experts stress reading ingredient lists and consulting professionals rather than relying solely on the “GLP‑1 Friendly” badge [1]. The guidance aims to prevent nutrient shortfalls while patients experience reduced food intake [1].
Sources (4 articles)
-
[1]
AP: GLP‑1 Friendly labels spread on foods as obesity drug use grows; FDA regulation lacking: Highlights the rapid rollout of “GLP‑1 Friendly” packaging, USDA’s limited approval, lack of FDA oversight, and dietitian recommendations for protein and fiber .
-
[2]
WBNS (Columbus, OH): FDA seeks removal of suicide risk warning from GLP‑1 medications Wegovy Saxenda Zepzola: Details the FDA’s formal request to drop the suicide warning, the 2005 origin of the label, and the agency’s meta‑analysis and claims‑based study showing no risk .
-
[3]
King5 (Seattle, WA): FDA asks GLP‑1 weight loss drug makers remove warning: Mirrors the WBNS report, emphasizing the same drugs, the historical warning, and the comprehensive safety review that found no increased psychiatric risk .
-
[4]
CNN: FDA asks removal of suicide warnings from GLP‑1 weight‑loss drugs after review finds no link: Provides trial numbers (91 trials, 107,910 patients), confirms no link to suicidal thoughts, notes earlier 2024 preliminary review, and mentions manufacturers’ lack of comment .
External resources (4 links)
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp?utm_medium=email&utm_source=govdelivery (cited 4 times)
- https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type#:~:text=GLP%252D1%2520RAs%2520are%2520a,make%2520someone%2520feel%2520full%2520longer. (cited 2 times)
- https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-says-no-evidence-yet-linking-weight-loss-drugs-suicidal-thoughts-2024-01-11/ (cited 1 times)